Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara. The company launched a phase 2/3 clinical trial program to test the therapy in Crohn’s disease, a new indication that would broaden
read moreTally another win for Bristol-Myers Squibb’s immunotherapy combination. Its Opdivo-Yervoy pairing grabbed an FDA approval in rare types of colon cancer for patients whose disease advanced on other treatments. More: Bristol-Myers Squibb's Opdivo-Yervoy combo wins right to challenge Merck's Keytruda
read moreNICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours. More: NICE backs use of dye for brain tumour removal Source: News
read moreNHS England has appointed a specialist GP to encourage the spread of innovations that integrate health and social care throughout England. More: NHS England appoints national clinical advisor for primary care Source: News
read moreJanssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease. More: Janssen launches PhII/III programme testing Tremfya in Crohn’s Source: News
read moreThe government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control. More: Gov’t launches £10 antimicrobial research competition Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals